They found that frequency and suppressive functions of CD39+ Tregs are decreased in MS patients and that the inhibition of Th17 cells was related to ADO production through the enzymatic activity of CD39 and CD73 [37]. The gene discussed is ENTPD1; the disease is myeloid sarcoma.